X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES LUPIN LTD ALKEM LABORATORIES/
LUPIN LTD
 
P/E (TTM) x - 27.9 - View Chart
P/BV x 7.1 2.9 241.8% View Chart
Dividend Yield % 0.6 0.6 107.9%  

Financials

 ALKEM LABORATORIES   LUPIN LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
LUPIN LTD
Mar-18
ALKEM LABORATORIES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,5891,465 108.5%   
Low Rs1,232727 169.4%   
Sales per share (Unadj.) Rs417.5349.6 119.4%  
Earnings per share (Unadj.) Rs56.35.6 1,012.9%  
Cash flow per share (Unadj.) Rs64.729.6 218.8%  
Dividends per share (Unadj.) Rs12.705.00 254.0%  
Dividend yield (eoy) %0.90.5 197.4%  
Book value per share (Unadj.) Rs292.9300.3 97.5%  
Shares outstanding (eoy) m119.57452.08 26.4%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.43.1 107.8%   
Avg P/E ratio x25.1197.2 12.7%  
P/CF ratio (eoy) x21.837.1 58.8%  
Price / Book Value ratio x4.83.6 131.9%  
Dividend payout %22.690.0 25.1%   
Avg Mkt Cap Rs m168,653495,502 34.0%   
No. of employees `000NA17.0 0.0%   
Total wages/salary Rs m9,17128,647 32.0%   
Avg. sales/employee Rs ThNM9,273.6-  
Avg. wages/employee Rs ThNM1,681.0-  
Avg. net profit/employee Rs ThNM147.4-  
INCOME DATA
Net Sales Rs m49,915158,042 31.6%  
Other income Rs m1,6451,504 109.4%   
Total revenues Rs m51,561159,545 32.3%   
Gross profit Rs m8,48231,475 26.9%  
Depreciation Rs m1,00610,859 9.3%   
Interest Rs m6712,044 32.8%   
Profit before tax Rs m8,45120,076 42.1%   
Minority Interest Rs m-114-71 160.5%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m1,6062,885 55.7%   
Profit after tax Rs m6,7312,513 267.9%  
Gross profit margin %17.019.9 85.3%  
Effective tax rate %19.014.4 132.3%   
Net profit margin %13.51.6 848.2%  
BALANCE SHEET DATA
Current assets Rs m27,062122,095 22.2%   
Current liabilities Rs m15,32450,956 30.1%   
Net working cap to sales %23.545.0 52.2%  
Current ratio x1.82.4 73.7%  
Inventory Days Days6785 78.6%  
Debtors Days Days41120 34.4%  
Net fixed assets Rs m12,610129,876 9.7%   
Share capital Rs m239904 26.4%   
"Free" reserves Rs m34,490134,866 25.6%   
Net worth Rs m35,027135,771 25.8%   
Long term debt Rs m1,21264,245 1.9%   
Total assets Rs m54,387263,054 20.7%  
Interest coverage x13.610.8 125.7%   
Debt to equity ratio x00.5 7.3%  
Sales to assets ratio x0.90.6 152.8%   
Return on assets %13.61.7 785.8%  
Return on equity %19.21.9 1,038.4%  
Return on capital %24.93.7 668.2%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56353,141 12.4%   
Fx outflow Rs m3,01219,335 15.6%   
Net fx Rs m3,55233,807 10.5%   
CASH FLOW
From Operations Rs m7,25917,512 41.4%  
From Investments Rs m1,864-14,073 -13.2%  
From Financial Activity Rs m-9,273-14,921 62.1%  
Net Cashflow Rs m-150-11,482 1.3%  

Share Holding

Indian Promoters % 66.9 46.6 143.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 33.1 11.3 292.9%  
FIIs % 0.0 31.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.1 -  
Shareholders   68,381 98,259 69.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 24, 2018 09:47 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS